Consensus statement on the use of clozapine during the COVID-19 pandemic
JournalJournal of psychiatry & neuroscience : JPN
PublisherCanadian Medical Association
MetadataShow full item record
With the ongoing coronavirus disease 2019 (COVID-19) pandemic, psychiatrists find themselves in the clinical situation of being asked by patients, family members and patient advocacy societies to help ensure access to clozapine as a medication critical for ongoing patient care. To provide clozapine prescribing guidance and facilitate regulatory agencies modifying laboratory monitoring and/or dispensing requirements, an expert advisory subgroup of the Treatment Response and Resistance in Psychosis working group developed the following background, recommendations and rationale as a consensus statement.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083188654&doi=10.1503%2fjpn.200061&partnerID=40&md5=0dc3ecc0fb112ea187d0e82342f634e5; http://hdl.handle.net/10713/12640
- Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.
- Authors: Berk M, Fitzsimons J, Lambert T, Pantelis C, Kulkarni J, Castle D, Ryan EW, Jespersen S, McGorry P, Berger G, Kuluris B, Callaly T, Dodd S
- Issue date: 2007
- Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
- Authors: Meo SA, Klonoff DC, Akram J
- Issue date: 2020 Apr
- Clozapine--a perspective. Accepted as a consensus statement by the ACNP Council, August 13, 1990.
- Authors: Shader RI
- Issue date: 1991 Feb
- Clozapine and COVID-19.
- Authors: Silva E, Gee S, Smith S, Gaughran F
- Issue date: 2020 Aug